tbuckley/cabot-search huggingface dataset:
Analysis of gut microbiota – An ever changing landscape
Authors: Michael J. Sadowsky, Christopher Staley, Cheryl Heiner, Richard Hall, Colleen R. Kelly, Lawrence Brandt, Alexander Khoruts
Journal: Gut Microbes (2017)

In the last two decades, the field of metagenomics has greatly expanded due to improvement in sequencing technologies allowing for a more comprehensive characterization of microbial communities. The use of these technologies has led to an unprecedented understanding of human, animal, and environmental microbiomes and have shown that the gut microbiota are comparable to an organ that is intrinsically linked with a variety of diseases. Characterization of microbial communities using next-generation sequencing-by-synthesis approaches have revealed important shifts in microbiota associated with debilitating diseases such as Clostridium difficile infection. But due to limitations in sequence read length, primer biases, and the quality of databases, genus- and species-level classification have been difficult. Third-generation technologies, such as Pacific Biosciences' single molecule, real-time (SMRT) approach, allow for unbiased, more specific identification of species that are likely clinically relevant. Comparison of Illumina next-generation characterization and SMRT sequencing of samples from patients treated for C. difficile infection revealed similarities in community composition at the phylum and family levels, but SMRT sequencing further allowed for species-level characterization - permitting a better understanding of the microbial ecology of this disease. Thus, as sequencing technologies continue to advance, new species-level insights can be gained in the study of complex and clinically-relevant microbial communities.
P3.01-028 Comparison of Touch Imprint Cytology and Section Histopathology in the Diagnostic of the Small Peripheral Lung Tumors
Authors: Masatoshi Kakihana, Junichi Maeda, Koichi Yoshida, Masaru Hagiwara, Naohiro Kajiwara, Tatsuo Ohira, Jun Matsubayashi, Toshitaka Nagao, Norihiko Ikeda
Journal: Journal of Thoracic Oncology (2017)
A Perspective on Out-of-Pocket Spending—Reply
Authors: Emily R. Adrion, Andrew M. Ryan, Brahmajee K. Nallamothu
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Genomic and Transcriptional Immunoediting of Acute Myeloid Leukemia in Response to Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Cristina Toffalori, Barbara Camisa, Andrea Calabria, Dejan Lazarevic, Orietta Spinelli, Massimo Bernardi, Alessandro Rambaldi, Elia Stupka, Cristina Barlassina, Claudio Bordignon, Attilio Bondanza, Chiara Bonini, Fabio Ciceri, Katharina Fleischhauer, Luca Vago
Journal: Blood (2011)
Prognostic Factors in Patients Receiving An Allogeneic Stem Cell Transplantation for Relapsed AML. Results of the Prospective AML 295 and 01/99 Studies
Authors: Jürgen Krauter, Gerhard Heil, Dieter Hoelzer, Hans Martin, Oliver G. Ottmann, Jürgen Finke, Michael Lübbert, Wolfgang Heit, Walter Fiedler, Lothar Kanz, Günter Schlimok, Hartmut Kirchner, Aruna Raghavachar, Wolfram Brugger, Hartmut Döhner, Arnold Ganser
Journal: Blood (2008)
Bimodal Degradation of MLL Protein by the Cell Cycle SCFSkp2 and APCCdc20 E3 Lilgases Assures Cell Cycle Execution: A Critical Regulatory Circuit Lost in Leukemogenic MLL-Fusions.
Authors: Han Liu, David Chen, Todd Westergard, Shugaku Takeda, Satoru Sasagawa, Emily H.-Y. Cheng, James J.-D. Hsieh
Journal: Blood (2007)
Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy–associated C3 glomerulopathy
Authors: Sophie Chauvet, Véronique Frémeaux-Bacchi, Florent Petitprez, Alexandre Karras, Laurent Daniel, Stéphane Burtey, Gabriel Choukroun, Yahsou Delmas, Dominique Guerrot, Arnaud François, Moglie Le Quintrec, Vincent Javaugue, David Ribes, Laurence Vrigneaud, Bertrand Arnulf, Jean Michel Goujon, Pierre Ronco, Guy Touchard, Frank Bridoux
Journal: Blood (2017)
Reciprocal Interaction of Monocytes and NK Cells by Activation-Induced Expression of Ligands for the Activating Immunoreceptor NKG2D.
Authors: Matthias Krusch, Mercedes Kloss, Andrea Peterfi, Ingrid Kumbier, Lothar Kanz, Peter A. Kiener, Helmut R. Salih
Journal: Blood (2005)
OA04.06 Examining Pleiotropic Associations of Genetic Risk Variants for Chronic Obstructive Pulmonary Disease with Lung Cancer Risk
Authors: Lori Sakoda, Khanh Thai, Nareg Roubinian, Carlos Iribarren, Catherine Schaefer, Neil Risch, Laurel Habel, Charles Quesenberry, Eric Jorgenson
Journal: Journal of Thoracic Oncology (2017)
Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal
Authors: Naoki Ikenaga, Zhen-Wei Peng, Kahini A Vaid, Susan B Liu, Shuhei Yoshida, Deanna Y Sverdlov, Amanda Mikels-Vigdal, Victoria Smith, Detlef Schuppan, Yury V Popov
Journal: Gut (2017)

<h3>Background/Aims</h3> We studied the role of lysyl oxidase-like 2 (LOXL2) in collagen crosslinking and hepatic progenitor cell (HPC) differentiation, and the therapeutic efficacy of a LOXL2-blocking monoclonal antibody on liver fibrosis progression/reversal in mice. <h3>Methods</h3> Anti-LOXL2 antibody, control antilysyl oxidase antibody or placebo was administered during thioacetamide (TAA)-induced fibrosis progression or during recovery. Therapeutic efficacy in biliary fibrosis was tested in BALB/c.<i>Mdr2−/−</i> and 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-fed mice. Collagen crosslinking, fibrosis progression and reversal were assessed histologically and biochemically. HPC differentiation was studied in primary EpCAM(+) liver cells in vitro. <h3>Results</h3> LOXL2 was virtually absent from healthy but strongly induced in fibrotic liver, with predominant localisation within fibrotic septa. Delayed anti-LOXL2 treatment of active TAA fibrosis significantly reduced collagen crosslinking and histological signs of bridging fibrosis, with a 53% reduction in morphometric collagen deposition. In established TAA fibrosis, LOXL2 inhibition promoted fibrosis reversal, with enhanced splitting and thinning of fibrotic septa, and a 45% decrease in collagen area at 4 weeks of recovery. In the Mdr2−/− and DDC-induced models of biliary fibrosis, anti-LOXL2 antibody similarly achieved significant antifibrotic efficacy and suppressed the ductular reaction, while hepatocyte replication increased. Blocking LOXL2 had a profound direct effect on primary EpCAM(+) HPC behaviour in vitro, promoting their differentiation towards hepatocytes, while inhibiting ductal cell lineage commitment. <h3>Conclusions</h3> LOXL2 mediates collagen crosslinking and fibrotic matrix stabilisation during liver fibrosis, and independently promotes fibrogenic HPC differentiation. By blocking these two convergent profibrotic pathways, therapeutic LOXL2 inhibition attenuates both parenchymal and biliary fibrosis and promotes fibrosis reversal.
Histones and Neutrophil Extracellular Traps Enhance Tubular Necrosis and Remote Organ Injury in Ischemic AKI
Authors: Daigo Nakazawa, Santhosh V. Kumar, Julian Marschner, Jyaysi Desai, Alexander Holderied, Lukas Rath, Franziska Kraft, Yutian Lei, Yuichiro Fukasawa, Gilbert W. Moeckel, Maria Lucia Angelotti, Helen Liapis, Hans-Joachim Anders
Journal: Journal of the American Society of Nephrology (2017)

Severe AKI is often associated with multiorgan dysfunction, but the mechanisms of this remote tissue injury are unknown. We hypothesized that renal necroinflammation releases cytotoxic molecules that may cause remote organ damage. In hypoxia-induced tubular epithelial cell necrosis in vitro, histone secretion from ischemic tubular cells primed neutrophils to form neutrophil extracellular traps. These traps induced tubular epithelial cell death and stimulated neutrophil extracellular trap formation in fresh neutrophils. In vivo, ischemia-reperfusion injury in the mouse kidney induced tubular necrosis, which preceded the expansion of localized and circulating neutrophil extracellular traps and the increased expression of inflammatory and injury-related genes. Pretreatment with inhibitors of neutrophil extracellular trap formation reduced kidney injury. Dual inhibition of neutrophil trap formation and tubular cell necrosis had an additive protective effect. Moreover, pretreatment with antihistone IgG suppressed ischemia-induced neutrophil extracellular trap formation and renal injury. Renal ischemic injury also increased the levels of circulating histones, and we detected neutrophil infiltration and TUNEL-positive cells in the lungs, liver, brain, and heart along with neutrophil extracellular trap accumulation in the lungs. Inhibition of neutrophil extracellular trap formation or of circulating histones reduced these effects as well. These data suggest that tubular necrosis and neutrophil extracellular trap formation accelerate kidney damage and remote organ dysfunction through cytokine and histone release and identify novel molecular targets to limit renal necroinflammation and multiorgan failure.
Tissue Oxygenation By Transfusion in Severe Anemia with Lactic Acidosis (TOTAL): A Prospective, Randomized, Non-Inferiority Trial of Blood Storage Duration
Authors: Aggrey Dhabangi, Brenda Ainomugisha, Christine M. Cserti-Gazdewich, Henry Ddungu, Dorothy Kyeyune, Ezra Musisi, Robert Opoka, Christopher P. Stowell, Walter H. Dzik
Journal: Blood (2015)
Novel Protein Agonist of Thrombopoiesis Acts Via a Physiocrine Pathway Distinct From That of Thrombopoietin
Authors: Minh-Ha T Do, Wei Zhang, Kyle Chiang, Chi-Fang Wu, Chulho Park, Quansheng Zhou, My-Nuong Vo, Xiang-Lei Yang, Lori Kunkel, Melissa A Ashlock, John D Mendlein, Rajesh Belani, Alain P Vasserot, Jeffry D Watkins
Journal: Blood (2011)
Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Patients (pts) Aged ≥60 Years.
Authors: Mohamed L. Sorror, Barry Storer, Brenda M. Sandmaier, David G. Maloney, Georg Franke, Judith Shizuru, Thomas Chauncey, Edward Agura, Richard T. Maziarz, Firoozeh Sahebi, Amelia A Langston, James C. Wade, Michael Maris, Benedetto Bruno, Andrew M. Yeager, Michael Pulsipher, Finn Petersen, Wolfgang A. Bethge, Peter A. McSweeney, Dietger Niederwieser, Karl G. Blume, Rainer F. Storb
Journal: Blood (2008)
P2.04-007 Role of F-18-Choline Petscan in Recurrence of Thymic Epithelial Tumors (TET)
Authors: Maria Bluthgen, Benjamin Besse, Francois Le Roy-Ladurie, Elie Fadel, Cecile Le Pechoux, Laurence Mabille
Journal: Journal of Thoracic Oncology (2017)
Refining Th Predictive Value of Secretory Phospholipase A2 In Sickle Cell Disease Patients with Acute Chest Syndrome
Authors: Lori Styles, Carrie Greene Wager, Richard J. Labotka, Kim Smith-Whitley, Alexis A. Thompson, Peter A. Lane, Lillian McMahon, Robin Miller, Susan D. Roseff, Dianne Gallagher, Rathi V. Iyer, Scott Miller
Journal: Blood (2010)
A Genetic Basis for Donor Variation in Generation of Prostaglandins and Leukotrienes in Stored RBCs Using a Mouse Model
Authors: James C. Zimring, Nicole H. Smith, Sean R. Stowell, Richard O. Francis, Eldad A. Hod, Jeanne E. Hendrickson, Larry J. Dumont, John Roback, Steven L. Spitalnik
Journal: Blood (2012)
Effect of progesterone and estrogen on cisplatin-induced apoptosis of lung cancer cells.
Authors: S. Karakaya, M. Grott, F. Mayer, F. Baertling, C. Beyer, M. Kipp, H. Kopp
Journal: Journal of Clinical Oncology (2011)

e21117 Background: The poor prognosis of patients with advanced non small cell lung cancer (NSCLC) is mainly due to chemotherapy resistance. Even with the advent of novel therapeutic compounds, median survival is as low as approximately 12 months. Sex hormones may play a role in the pathogenesis of lung cancer. Indeed, there is evidence that estrogen stimulates tumor growth. The role of progesterone, however, remains unclear. We therefore set out to establish the influence of estrogen and progesterone on in vitro chemo-resistance of the NSCLC cell line A549 against cisplatin. Methods: Effects of estrogen and progesterone pre-treatment before exposure to cisplatin were measured utilizing proliferation and apoptosis assays. Furthermore, the influence of sex hormones on the expression of copper transporter 1 (CTR1), which is responsible for the intracellular accumulation of cisplatin, and on activation-levels of caspase 3-7, 8, 9 after cisplatin exposure were determined using semi-quantitative RT-PCR and caspase assays. Results: A549 cells express estrogen receptor (ER) alpha, ER-beta, and progesterone receptor (PR). Both estrogen and progesterone conveyed chemo-resistance in vitro by reducing cisplatin induced apoptosis. Anti-apoptotic effects of progesterone and estrogen were paralleled by significant prevention of cisplatin-induced loss of metabolic activity. These effects could not be antagonized by fulvestrant and mifepristone, respectively. Cisplatin induced apoptosis via activation of caspase 8, 9 and consequent activation of the caspase effector complex 3-7. Estrogen and progesterone attenuated the levels of caspase activation. CTR1 expression was not modulated by estrogen or progesterone. Conclusions: These results suggest that estrogen and progesterone may play an important role in chemotherapy resistance in NSCLC. The underlying mechanisms include interference with caspase-dependent apoptosis, but not downregulation of CTR1 or transcriptional regulation of caspase expression. We propose that non-classical sex hormone signaling pathways via membranous receptors may play a key role in this context, because fulvestrant and mifepristone failed to antagonize the described effects.
The RAS–Effector Interaction as a Drug Target
Authors: Adam B. Keeton, E. Alan Salter, Gary A. Piazza
Journal: Cancer Research (2017)

About a third of all human cancers harbor mutations in one of the K-, N-, or HRAS genes that encode an abnormal RAS protein locked in a constitutively activated state to drive malignant transformation and tumor growth. Despite more than three decades of intensive research aimed at the discovery of RAS-directed therapeutics, there are no FDA-approved drugs that are broadly effective against RAS-driven cancers. Although RAS proteins are often said to be "undruggable," there is mounting evidence suggesting it may be feasible to develop direct inhibitors of RAS proteins. Here, we review this evidence with a focus on compounds capable of inhibiting the interaction of RAS proteins with their effectors that transduce the signals of RAS and that drive and sustain malignant transformation and tumor growth. These reports of direct-acting RAS inhibitors provide valuable insight for further discovery and development of clinical candidates for RAS-driven cancers involving mutations in RAS genes or otherwise activated RAS proteins. Cancer Res; 77(2); 221-6. ©2017 AACR.
Host Tissue PD-L1 Separates GVL Effect from Gvhd after Temporary Depletion of Donor CD4+ T Cells Early after HCT
Authors: Xiong Ni, Qingxiao Song, Ruishu Deng, Hua Jin, Kaniel M. Cassady, Mingfeng Zhang, Stephen J. Forman, Paul J. Martin, Jianmin Wang, Defu Zeng
Journal: Blood (2015)
Selective Depletion of Recipient-Alloreactive T-Cells While Retaining Viral-Specific and Memory T-Cells Enables Safe and Efficacious Haplo-Identical HSCT
Authors: Jurjen H.L. Velthuis, Liesbeth De Jong, Radia Sidi Boumédine, Marie-Pier Giard, Denis-Claude Roy, Manfred Rüdiger
Journal: Blood (2014)
Flow Cytometric Detection of Liposomes in the CSF of Patients with NHL/ALL, Treated with Intrathecal Liposomal Cytarabine: Synonymous of Toxicity?
Authors: Francisco Javier Peñalver, Martínez-Barranco Pilar, Lucía Villalón, Manuel Barón, L Martín, Pilar Ricard, Karmele Arribalzaga, María José Garcia Bueno, Alberto Orfao
Journal: Blood (2014)
P1 Pleural effusion size estimation: US, CXR or CT?
Authors: C Brockelsby, M Ahmed, M Gautam
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> Chest X-ray (CXR), CT and Ultrasound (US) are commonly used to evaluate the size of pleural effusions. Accurate description of size is important in the communication of findings and urgency of intervention. With currently no standardised measurement system, significant variation in description of size by CXR, CT or US exists. The use of terms 'small, moderate, and large' is common, with no consensus on the limits of these sizes. This study looked at correlation between qualitative description of effusion size by different imaging modalities and volume of effusion recorded following aspiration. <h3>Methods</h3> This was a retrospective analysis of patients referred for pleural tap and/or drain after CXR and/or CT. CXR/CT reports were collected from PACS, US reports from the local US database, accessed by at least two US-trained Respiratory physicians. Effusion size was estimated by the recognised method of counting intercostal spaces (ICS) from costophrenic angle (small- localised to 1 ICS, medium 2–3 ICS, large ≥4 ICS). Effusion size reported was compared to actual volume of fluid drained (till 'dry' or 'safe aspiration'). For the purpose of this study, effusions &lt;500 mL were characterised as small, 500–1000 mL moderate and &gt;1000 mL large. Correlation was analysed using Spearman's correlation. <h3>Results</h3> 312 patients were referred April 2014–December 2015. 133 patients were excluded due to insufficient data, 179 patients' data analysed. US pleural effusion size estimation correlated most closely with actual volume of fluid drained (r = 0.833, N = 179, P &lt; 0.0001) vs. CXR (r = 0.548, N = 129, P &lt; 0.001) and CT (r = 0.489, N = 107, P &lt; 0.001). The error rate in size estimation was 41% (53/129) for CXR, 57% (61/107) for CT and 16% (28/179) for US. In particular, 29% (31/107) patients with 'small' tapped effusions were reported to be 'medium/large' effusions by CT scan. CT most commonly overestimated fluid present; whilst US tended to underestimate the few cases where it was inaccurate. <h3>Conclusions</h3> This study demonstrates that US may be the most accurate modality when assessing the size of pleural effusions. CT imaging may over represent the volume of fluid present. Where imaging reports guide further management, reliability and consistency is essential to avoid unnecessary/urgent intervention and patient anxiety.
A Germline Mutation in Cathepsin B in a Child with ALL Points towards a Key Role for This Enzyme in L-Asparaginase Pharmacokinetics.
Authors: Laurens T. van der Meer, Esmé Waanders, Marloes Levers, Hanka Venselaar, Debbie Roeleveld, Joachim Boos, Claudia Lanvers-Kaminsky, Roland P. Kuiper, Peter M. Hoogerbrugge, Frank N. van Leeuwen, D. Maroeska W.M. te Loo
Journal: Blood (2012)
P3.07-021 Prevalence of EGFR Mutations in Brazilian Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer
Authors: Ellias Abreu Lima, Paulo Guilherme Sales, Israel Vilaça, Fernanda Perillo, Flavia Almeida, Graziella Martins, Mariana Gonçalves, Joseane Toledo, Poliana Giovani, Wania Silva
Journal: Journal of Thoracic Oncology (2017)
患者の苦痛,症状の負荷,及び治療関連情報と支援ニーズに及ぼす新しい看護師先導前化学療法教育介入(ChemoEd)の影響:ランダム化対照試験の結果
Authors: S Aranda, M Jefford, P Yates, K Gough, J Seymour, P Francis, C Baravelli, S Breen, P Schofield
Journal: Annals of Oncology (2012)
Prognostic Significance of Somatic Mutations in Treatment of AML in Salvage Setting: A Retrospective Analysis
Authors: Birendra KC, Hagop M. Kantarjian, Guillermo Garcia-Manero, Naval Daver, Gautam Borthakur, Marina Konopleva, Michael Andreeff, Dai Chihara, Tapan Kadia, Prithviraj Bose, Zeev Estrov, Naveen Pemmaraju, Farhad Ravandi, Jorge E. Cortes
Journal: Blood (2015)
S42 Eradication success of non-tuberculous mycobacterial infections in a paediatric cystic fibrosis population
Authors: DA Hughes, A Malfitano, A Davenport, SB Carr
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> Non-tuberculous mycobacterial (NTM) infections are being increasingly identified within adult and paediatric Cystic Fibrosis (CF) populations. They present a diagnostic and management challenge, requiring intensive treatment regimens with little literature on eradication success within children. In this retrospective study we describe a cohort of paediatric CF patients with NTM infection, examine treatment duration and eradication. <h3>Methods</h3> All new isolates of NTM during a five year period (2011–15) were identified at a single tertiary paediatric CF centre with a population of 450 children. Groups were separated into Mycobacterium abscessus complex (MABSC), Mycobacterium avium complex (MAC) and other mycobacterial infections <i>(M. kansasii, M. malmoense)</i>. Data on demographics and NTM treatment were collected and analysed. Eradication is defined as 4 clear samples at a year after stopping treatment. <h3>Results</h3> 33 patients grew at least one new isolate of NTM: MABSC (n = 20, 5 of which grew other NTM species in temporally distinct episodes), MAC (n = 12) &amp; other NTMs (n = 5, mainly <i>M. kansasii</i>). 51% female. Median age at 1st isolation 12.3 yrs (range, 4–17.3), and FEV1 79.5% predicted (50–116%). 10 (26%) initial isolates were from BAL. For MABSC: 4 (20%) had ABPA and 6 (30%) CFRD. All patients met ATS/IDSA criteria for diagnosis and were treated in accordance with national consensus guidelines. Spontaneous clearance was seen in 100% of other NTM infections. For data on clearance and treatment of MABSC and MAC, see Table 1. 9/14 who completed NTM treatment showed culture conversion at 3 months. Only 2 children with negative cultures at 3 months went on to have subsequent positive microbiology. <h3>Conclusion</h3> This is the first report discussing treatment success for NTM in a large paediatric cohort. Although single centre, there is a similar incidence of NTM to that reported for adult CF populations. Spontaneous clearance is more common with MAC (42%) and other NTM infections compared to MABSC (10%). To date 53% of treated MABSC are considered eradicated 12 months post treatment. Early culture conversion appears to be linked with treatment success. Further studies are needed to identify if a lack of early clearance should identify children appropriate for further inpatient induction therapy.
Changes in Differential Gene and Protein Expression Patterns during Development of Cord Blood (CB) Versus Adult Peripheral Blood (APB) Monocyte (Mo) into Mature Dendritic Cells (mDC): Insight into Immaturity of CB DC Immunity.
Authors: Hong Jiang, Cheryl Wade-Harris, Megan Lim, Laxmi Baxi, Mitchell S. Cairo
Journal: Blood (2006)
P3.02c-090 The Role of ERCC-1 Polymorphisms as Predictive Biomarker of Response to Nivolumab in Advanced NSCLC
Authors: Marco Aiello, Hector Soto Parra, Laura Noto, Nunzio Restuccia, Paolo Vigneri, Sabrina Paratore
Journal: Journal of Thoracic Oncology (2017)
P1.05-072 Predictors and Patterns of Lymph Node Metastasis in Small Peripheral Non-Small Cell Lung Cancer
Authors: Jun-Tao Lin, Xue-Ning Yang, Li-Xu Yan, Si-Yun Wang, Wen-Zhao Zhong, Qiang Nie, Ri-Qiang Liao, Song Dong, Ben-Yuan Jiang, Yi Long Wu
Journal: Journal of Thoracic Oncology (2017)